title: Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.
abstract: The nasopharynx-associated lymphoid tissue (NALT) of humans and other mammals is associated with immunity against airborne infections, though it is generally considered to be a secondary component of the mucosa-associated lymphoid system. We found that protective immunity to a virulence factor of nasal mucosa-colonizing Staphylococcus aureus, staphylococcal enterotoxin B (SEB), requires a functional NALT. We examined the role of NALT using intranasal (IN) vaccination with a recombinant SEB vaccine (rSEBv) combined with an adjuvant in a mouse model of SEB-induced toxic shock. The rSEBv was rapidly internalized by NALT cells at the mucosal barrier, and transport into NALT was accelerated by inclusion of a Toll-like receptor 4 (TLR4) agonist. Vaccine-induced germinal centers of B cells formed within NALT, accompanied by elevated levels of IgA(+) and IgG(+) cells, and these were further increased by TLR4 activation. The NALT was the site of specific anti-rSEBv IgA and IgG production but was also influenced by intraperitoneal (IP) inoculation and perhaps other isolated lymphoid follicles observed within the nasal cavity. Vaccination by the IN route generated robust levels of anti-rSEBv IgA in saliva, nasal secretions, and blood compared to much lower levels after IP vaccination. IN vaccination also induced secretion of anti-rSEBv IgG in the blood and nasal secretions. Significantly, the efficacy of IN vaccination was dependent on NALT, as surgical removal resulted in greater sensitivity to IN challenge with wild-type SEB. Thus, protective immunity to SEB within the nasal sinuses was elicited by responses originating in NALT.
authors.affiliation: United States Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Frederick, MD 21702, USA. stefan.fernandez@us.army.mil
authors.forename: Stefan
authors.initials: S
authors.lastname: Fernandez
authors.forename: Emily D
authors.initials: ED
authors.lastname: Cisney
authors.forename: Shannan I
authors.initials: SI
authors.lastname: Hall
authors.forename: Robert G
authors.initials: RG
authors.lastname: Ulrich
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D012634:Bodily Secretions / Q000276:immunology; D004195:Disease Models, Animal; D004768:Enterotoxins / Q000276:immunology; D005260:Female; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008221:Lymphoid Tissue / Q000276:immunology*; D008322:Mammals; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology* / Q000382:microbiology; D009305:Nasopharynx / Q000276:immunology* / Q000382:microbiology; D012463:Saliva / Q000276:immunology; D012772:Shock, Septic / Q000276:immunology* / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000276:immunology* / Q000517:prevention & control; D013209:Staphylococcal Vaccines / Q000008:administration & dosage; D013211:Staphylococcus aureus / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D004768:Enterotoxins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D013209:Staphylococcal Vaccines; C031818:enterotoxin B, staphylococcal